본문 바로가기
KERD
논문KCI 등재

Diagnosis and treatment of multidrug-resistant tuberculosis

정진홍|장종걸
영남대학교 의과대학 (Yeungnam University College of Medicine)|2020.10|Journal of Yeungnam Medical Science|제37권 제4호|pp. 277-285|DOI 10.12701/yujm.2020.00626

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

TreatmentDiagnosisMultidrug-resistant tuberculosis
주제분류의학일반

초록

Tuberculosis (TB) is still a major health problem worldwide. Especially, multidrug-resistant TB (MDR-TB), which is defined as TB that shows resistance to both isoniazid and rifampicin, is a barrier in the treatment of TB. Globally, approximately 3.4% of new TB patients and 20% of the patients with a history of previous treatment for TB were diagnosed with MDR-TB. The treatment of MDR-TB requires medications for a long duration (up to 20–24 months) with less effective and toxic second-line drugs and has unfavorable outcomes. However, treatment outcomes are expected to improve due to the introduction of a new agent (bedaquiline), repurposed drugs (linezolid, clofazimine, and cycloserine), and technological advancement in rapid drug sensitivity testing. The World Health Organization (WHO) released a rapid communication in 2018, followed by consolidated guidelines for the treatment of MDR-TB in 2019 based on clinical trials and an individual patient data meta-analysis. In these guidelines, the WHO suggested reclassification of second-line anti-TB drugs and recommended oral treatment regimens that included the new and repurposed agents. The aims of this article are to review the treatment strategies of MDR-TB based on the 2019 WHO guidelines regarding the management of MDR-TB and the diagnostic techniques for detecting resistance, including phenotypic and molecular drug sensitivity tests.

Abstract

Tuberculosis (TB) is still a major health problem worldwide. Especially, multidrug-resistant TB (MDR-TB), which is defined as TB that shows resistance to both isoniazid and rifampicin, is a barrier in the treatment of TB. Globally, approximately 3.4% of new TB patients and 20% of the patients with a history of previous treatment for TB were diagnosed with MDR-TB. The treatment of MDR-TB requires medications for a long duration (up to 20–24 months) with less effective and toxic second-line drugs and has unfavorable outcomes. However, treatment outcomes are expected to improve due to the introduction of a new agent (bedaquiline), repurposed drugs (linezolid, clofazimine, and cycloserine), and technological advancement in rapid drug sensitivity testing. The World Health Organization (WHO) released a rapid communication in 2018, followed by consolidated guidelines for the treatment of MDR-TB in 2019 based on clinical trials and an individual patient data meta-analysis. In these guidelines, the WHO suggested reclassification of second-line anti-TB drugs and recommended oral treatment regimens that included the new and repurposed agents. The aims of this article are to review the treatment strategies of MDR-TB based on the 2019 WHO guidelines regarding the management of MDR-TB and the diagnostic techniques for detecting resistance, including phenotypic and molecular drug sensitivity tests.

참고문헌 (60)

  1. "Global health estimates 2016: deaths by cause, age, sex, by country and by region, 2000-2016" (2018)[URL]
  2. "WHO consolidated guidelines on drug-resistant tuberculosis treatment" (2019)[URL]
  3. "Global tuberculosis report 2015" (2015)[URL]
  4. "Global tuberculosis report 2019" (2019)[URL]
  5. "Treatment guidelines for drug-resistant tuberculosis, 2016 update" (2016)[URL]
  6. David HL, "Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis", Appl Microbiol, 20, pp.810~814 (1970)
  7. Kim SJ, "Drug-susceptibility testing in tuberculosis : methods and reliability of results", Eur Respir J, 25, pp.564~569 (2005)
  8. Zhang Y, "Mechanisms of drug resistance in Mycobacterium tuberculosis : update 2015", Int J Tuberc Lung Dis, 19, pp.1276~1289 (2015)
  9. Kendall EA, "Burden of transmitted multidrug resistance in epidemics of tuberculosis : a transmission modelling analysis", Lancet Respir Med, 3, pp.963~972 (2015)
  10. Canetti G, "Mycobacteria : laboratory methods for testing drug sensitivity and resistance", Bull World Health Organ, 29, pp.565~578 (1963)
  11. "Guidelines for surveillance of drug resistance in tuberculosis" (2009)[URL]
  12. CanettI G, "Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation", Rev Tuberc Pneumol(Paris), 27, pp.217~272 (1963)
  13. Schaberg T, "Rapid drug susceptibility testing of Mycobacterium tuberculosis using conventional solid media", Eur Respir J, 8, pp.1688~1693 (1995)
  14. "Use of liquid TB culture and drug susceptibility testing (DST) in low and medium income setting. Summary report of the Expert Group Meeting on the use of liquid culture media" (2007)[URL]
  15. 고원중, "Rapid Diagnosis of Tuberculosis and Multidrug Resistance Using a MGIT 960 System", Annals of Laboratory Medicine, 32(4), pp.264~269 (2012), 대한진단검사의학회[DOI]
  16. Coll F, "Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences", Genome Med, 7, pp.51~ (2015)
  17. "Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB)" (2008)[URL]
  18. "The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin" (2016)[URL]
  19. "WHO consolidated guidelines on tuberculosis. Module 3: diagnosis–rapid diagnostics for tuberculosis detection" (2020)[URL]
  20. Hillemann D, "Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens", J Clin Microbiol, 45, pp.2635~2640 (2007)
  21. "GenoType MTBDRplus, ver. 2.0. Instructions for use (IFU-304A-06)" (2008)[URL]
  22. Ling DI, "GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis : a meta-analysis", Eur Respir J, 32, pp.1165~1174 (2008)
  23. Theron G, "The diagnostic accuracy of the GenoType(®)MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs", Cochrane Database Syst Rev, (10), pp.CD010705~ (2014)
  24. "Molecular assays intended as initial tests for the diagnosis of pulmonary and extrapulmonary TB and rifampicin resistance in adults and children: rapid communication" (2020)[URL]
  25. El-Hajj HH, "Detection of rifampin resistance in Mycobacterium tuberculosis in a single tube with molecular beacons", J Clin Microbiol, 39, pp.4131~4137 (2001)
  26. Denkinger CM, "Xpert MTB", RIF assay for the diagnosis of extrapulmonary tuberculosis : a systematic review and meta-analysis, 2014, pp.44, 435~446
  27. Dorman SE, "Xpert MTB", RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance : a prospective multicentre diagnostic accuracy study, 2018, pp.18, 76~84
  28. Feliciano CS, "Accuracy of whole genome sequencing versus phenotypic(MGIT)and commercial molecular tests for detection of drug-resistant Mycobacterium tuberculosis isolated from patients in Brazil and Mozambique", Tuberculosis(Edinb), 110, pp.59~67 (2018)
  29. Witney AA, "Clinical use of whole genome sequencing for Mycobacterium tuberculosis", BMC Med, 14, pp.46~ (2016)
  30. CRyPTIC Consortium and the 100,000 Genomes Project, "Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing", N Engl J Med, 379, pp.1403~1415 (2018)
  31. Katale BZ, "Whole genome sequencing of Mycobacterium tuberculosis isolates and clinical outcomes of patients treated for multidrug-resistant tuberculosis in Tanzania", BMC Genomics, 21, pp.174~ (2020)
  32. "The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide" (2018)[URL]
  33. "Guidelines for the programmatic management of drug-resistant tuberculosis-2011 update" (2011)[URL]
  34. "Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB)" (2011)[URL]
  35. Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, "Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis", Lancet, 392, pp.821~834 (2018)
  36. Bastos ML, "An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis", Eur Respir J, 49, pp.1600803~ (2017)
  37. Joint Committee for the Revision of Korean Guidelines for Tuberculosis, "Korean guidelines for tuberculosis. 4th ed", Korea Centers for Disease Control and Prevention, ~ (2020)
  38. Moadebi S, "Fluoroquinolones for the treatment of pulmonary tuberculosis", Drugs, 67, pp.2077~2099 (2007)
  39. Sirgel FA, "gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis", J Antimicrob Chemother, 67, pp.1088~1093 (2012)
  40. Migliori GB, "Protecting the tuberculosis drug pipeline : stating the case for the rational use of fluoroquinolones", Eur Respir J, 40, pp.814~822 (2012)
  41. Kang YA, "Choice between levofloxacin and moxifloxacin and multidrug-resistant tuberculosis treatment outcomes", Ann Am Thorac Soc, 13, pp.364~370 (2016)
  42. Nahid P, "Treatment of drug-resistant tuberculosis. An official ATS", CDC, IDSA clinical practice guideline, pp.Am J Respir Crit Care Med, 2019[DOI]
  43. Livermore DM, "Linezolid in vitro : mechanism and antibacterial spectrum", J Antimicrob Chemother, 51(Suppl 2), pp.ii9~ii16 (2013)
  44. Lan Z, "Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis : an individual patient data meta-analysis", Lancet Respir Med, 8, pp.383~394 (2020)
  45. Koh WJ, "Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis : updated analysis of 51 patients", J Antimicrob Chemother, 67, pp.1503~1507 (2012)
  46. Sotgiu G, "Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis", Eur Respir J, 40, pp.1430~ (2012)
  47. Koul A, "Diarylquinolines target subunit c of mycobacterial ATP synthase", Nat Chem Biol, 3, pp.323~324 (2007)
  48. Rouan MC, "Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis", Antimicrob Agents Chemother, 56, pp.1444~1451 (2012)
  49. Diacon AH, "Multidrug-resistant tuberculosis and culture conversion with bedaquiline", N Engl J Med, 371, pp.723~732 (2014)
  50. Diacon AH, "The diarylquinoline TMC207 for multidrug-resistant tuberculosis", N Engl J Med, 360, pp.2397~2405 (2009)
  51. Centers for Disease Control and Prevention, "Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate(Sirturo)for the treatment of multidrug-resistant tuberculosis", MMWR Recomm Rep, 62(RR-09), pp.1~12 (2013)
  52. Matsumoto M, "OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice", PLoS Med, 3, pp.e466~ (2006)
  53. Barry PJ, "Novel agents in the management of Mycobacterium tuberculosis disease", Curr Med Chem, 14, pp.2000~2008 (2007)
  54. Kim CT, "Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis : a multicentre cohort study in Korea", Eur Respir J, 51, pp.1702467~ (2018)
  55. Mok J, "Final treatment outcomes of delamanid-containing regimens in patients with MDR-", XDR-TB in South Korea, 2019, pp.54, 1900811~
  56. Ferlazzo G, "Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study", Lancet Infect Dis, 18, pp.536~544 (2018)
  57. Lange C, "Limited benefit of the new shorter multidrug-resistant tuberculosis regimen in Europe", Am J Respir Crit Care Med, 194, pp.1029~1031 (2016)
  58. Cegielski JP, "Multidrug-resistant tuberculosis treatment outcomes in relation to treatment and initial versus acquired second-line drug resistance", Clin Infect Dis, 62, pp.418~430 (2016)
  59. Van Deun A, "Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis", Am J Respir Crit Care Med, 182, pp.684~692 (2010)
  60. Nunn AJ, "A trial of a shorter regimen for rifampin-resistant tuberculosis", N Engl J Med, 380, pp.1201~1213 (2019)

관련 논문AI추천

Drug susceptibility testing for Mycobacterium tuberculosis: a narrative review김창기대한임상미생물학회 · Annals of Clinical Microbiology2025 · 제28권 제4호Medical Treatment of Pulmonary Multidrug-Resistant Tuberculosis심태선, 조경욱대한감염학회 · Infection and Chemotherapy2013 · 제45권 제4호내성 결핵균의 실태 및 치료임재준대한내과학회 · 대한내과학회지2009 · 제77권 제2호한국에서 다제내성결핵에 대한 경구 단기 치료 요법권용수대한내과학회 · 대한내과학회지2023 · 제98권 제4호Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea김경종, 양정성, 이승헌, 최홍조대한진단검사의학회 · Annals of Laboratory Medicine2018 · 제38권 제6호Drug Resistance Patterns of Multidrug- and Extensively Drug-Resistant Tuberculosis in Korea: Amplification of Resistance to Oral Second-line Drugs김창기, 김희진, 이경원, So Youn Shin대한진단검사의학회 · Annals of Laboratory Medicine2017 · 제37권 제4호

이 간행물의 다른 논문 (16건)

Advances in the science and treatment of respiratory diseasesJin Hong Chungpp. 251-252An update on the role of bronchoscopy in the diagnosis of pulmonary disease안준홍pp. 253-261Biological treatments for severe asthma진현정pp. 262-268Therapeutic potential of targeting kinase inhibition in patients with idiopathic pulmonary fibrosisSuji Kim, 우창훈, 임재향pp. 269-276Novel respiratory infectious diseases in Korea김현정pp. 286-295
원문 보기